Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events

Affiliations

¹ Division of Rheumatology, University of Chicago Medical Center, Chicago, Illinois.
² Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts.
³ Hospital for Special Surgery, Division of Rheumatology, Weill Cornell Medicine, New York, New York.

Comment

Pankti Reid et al. JAMA Oncol. 2023.

. 2023 May 1;9(5):723-724.

doi: 10.1001/jamaoncol.2023.0100.

¹ Division of Rheumatology, University of Chicago Medical Center, Chicago, Illinois.
² Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, Massachusetts.
³ Hospital for Special Surgery, Division of Rheumatology, Weill Cornell Medicine, New York, New York.

No abstract available

Comment in

Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events-Reply.
van Not OJ, Verheijden RJ, Suijkerbuijk KPM. van Not OJ, et al. JAMA Oncol. 2023 May 1;9(5):724. doi: 10.1001/jamaoncol.2023.0103. JAMA Oncol. 2023. PMID: 36892850 No abstract available.

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.
van Not OJ, Verheijden RJ, van den Eertwegh AJM, Haanen JBAG, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JB, Hospers GAP, Kamphuis AM, Kapiteijn E, May AM, de Meza MM, Piersma D, van Rijn R, Stevense-den Boer MA, van der Veldt AAM, Vreugdenhil G, Blokx WAM, Wouters MJM, Suijkerbuijk KPM. van Not OJ, et al. JAMA Oncol. 2022 Dec 1;8(12):1794-1801. doi: 10.1001/jamaoncol.2022.5041. JAMA Oncol. 2022. PMID: 36301521 Free PMC article.